Your patient campaign worked. The search ad connected. The website answered the right questions. The patient spoke with a healthcare professional and received a prescription. From a traditional marketing perspective, that can look like a successful conversion.
Then the patient reaches the pharmacy counter and the claim is rejected.
For pharma marketers, that moment deserves more attention. A modern strategy for reducing prescription abandonment should account for what happens after a patient decides to start treatment, not simply what happens before the prescription is written. Claim rejection, unexpected costs, prior authorization requirements, and confusing next steps can turn an apparently successful patient journey into an abandoned prescription.
ARS Pharmaceuticals’ approach to rejected neffy claims offers an interesting example of how manufacturers may rethink this overlooked part of the patient experience.
Table of Contents
- Why prescription abandonment is a marketing problem
- What ARS Pharma’s neffy strategy tells marketers
- Building post-prescription friction into patient journey mapping
- Measuring marketing beyond clicks and prescriptions
- Conclusion
- Frequently asked questions
Why Prescription Abandonment Is a Marketing Problem
Marketers often spend heavily to remove friction from the upper and middle parts of the patient journey. They optimize search, patient education, disease awareness, HCP conversations, telehealth pathways, and calls to action. However, the journey can become considerably harder once the prescription enters the pharmacy system.
A rejected claim can occur because of formulary restrictions, prior authorization requirements, coverage issues, or other administrative barriers. Consequently, the patient who was highly motivated minutes earlier suddenly faces another decision: keep trying or walk away.
That is more than a market-access issue. It is also a patient-experience and marketing problem.
Research from IQVIA has shown a strong relationship between patient costs and prescription abandonment. Administrative burdens, high out-of-pocket costs, and lengthy approval processes can all become barriers between receiving a prescription and starting treatment.
Therefore, marketers may need to broaden their definition of conversion. A prescription written is important. Yet a prescription successfully obtained by the patient may be a more meaningful milestone.
What ARS Pharma’s neffy Strategy Tells Marketers
ARS Pharmaceuticals provides a useful case study. In May 2026, the company introduced an automated retail pharmacy solution designed specifically to reduce abandonment after rejected neffy claims. According to ARS Pharma, the point-of-sale program can convert an eligible denied claim to a $199 cash price.
The company describes neffy Retail Ready as an automated pharmacy solution intended to reduce administrative burden, callbacks, and delays. When coverage or an approved prior authorization provides a better outcome, eligible patients can receive that price. However, when an eligible commercially insured patient’s claim is denied or a prior authorization is rejected, the retail pathway can automatically convert to the $199 option.
Importantly, this approach does not eliminate every access challenge. Nor does a $199 price guarantee that every patient will fill a prescription. Still, the program illustrates an important principle for reducing prescription abandonment: when access friction appears, the patient’s next step should be obvious and immediate.
Previously, ARS Pharma had also established neffyConnect and partnered with BlinkRx to provide access support and affordability options. At launch, the company said eligible commercially insured patients could pay $25 for two single-use neffy devices through a copay savings program. It also offered a $199 cash option for certain patients facing coverage or affordability barriers.
For marketers, the interesting part is not simply the discount. Instead, it is the attempt to connect patient access infrastructure with the exact moment when someone encounters friction.
Building Post-Prescription Friction Into the Patient Journey
Most patient journey maps contain familiar stages: awareness, education, consideration, HCP discussion, treatment decision, and adherence. Yet the space between “prescribed” and “therapy started” deserves far more attention.
A stronger prescription abandonment strategy starts by mapping the points where patients are most likely to encounter access barriers or drop off.
For example, what happens when the pharmacy receives the prescription but the payer rejects the claim? Does the patient understand why? Does the pharmacist have a straightforward alternative pathway? Can the physician’s office respond quickly? Most importantly, does the patient know what to do next?
These questions matter because motivation has a shelf life. A patient who has already searched, learned, scheduled an appointment, discussed treatment, and obtained a prescription has invested significant effort. Nevertheless, another layer of complexity can stop that momentum.
Data reinforces the risk. IQVIA reported that abandonment increases sharply as patient out-of-pocket costs rise. Its analysis found abandonment below 5% for prescriptions with no out-of-pocket cost, compared with 45% when patient costs exceeded $125.
Therefore, patient experience teams should consider pharmacy friction alongside website friction, call-center friction, and enrollment friction. The pharmacy counter is another important touchpoint, even though marketers do not fully control it.
Measuring Marketing Beyond Clicks and Prescriptions
This raises a bigger measurement question. What exactly counts as a successful pharma patient campaign?
Clicks and site engagement provide useful signals. HCP visits, patient requests, and new prescriptions move closer to business outcomes. However, none guarantees that the patient actually starts therapy.
That makes prescription abandonment and patient access relevant to marketing performance, not just market access.
Teams could examine the journey as a connected funnel: campaign exposure to patient action, patient action to HCP conversation, prescription to adjudication, and adjudication to successful fill. Instead of stopping measurement at prescription volume, brands can look for where intended demand disappears.
The goal is not to make marketing responsible for every payer decision. Rather, marketing, market access, patient services, analytics, and commercial teams can share a clearer picture of the experience.
This perspective may also change campaign planning. For instance, patient communications can explain access resources before patients encounter problems. HCP materials can clarify available support pathways. Meanwhile, digital experiences can direct patients toward appropriate assistance without forcing them to restart their search when something goes wrong.
For broader industry insights on connecting digital strategy with healthcare audiences, eHealthcare Solutions provides resources for healthcare marketers.
Ultimately, marketers should ask a simple question after every apparent conversion: did the patient actually get the therapy?
Conclusion
ARS Pharma’s neffy retail initiative highlights a part of the patient journey that pharma marketing can easily overlook. Getting a patient interested enough to seek treatment is only part of the challenge. Getting that patient through coverage, cost, and pharmacy friction is another.
An effective approach to reducing prescription abandonment treats the post-prescription experience as part of the broader patient journey. That means identifying claim rejection points, understanding affordability barriers, creating clearer next steps, and measuring what happens between prescription and fill.
For marketers, the opportunity is not to take over market access. Instead, it is to stop treating access as something that happens outside the patient experience.
A campaign has not necessarily succeeded because it generated a click or even contributed to a prescription. The more important question may be what happened at the pharmacy counter next.
Frequently Asked Questions
What is prescription abandonment?
Prescription abandonment generally occurs when a patient receives a prescription but does not ultimately obtain the medication. Cost, insurance restrictions, administrative delays, and other access barriers can contribute.
Why should pharma marketers care about rejected pharmacy claims?
Rejected claims can interrupt the patient journey after marketing has successfully generated awareness and action. Therefore, they can reduce the number of motivated patients who ultimately start therapy.
How can pharma brands reduce prescription abandonment?
Reducing prescription abandonment starts with identifying the barriers between prescribing and treatment initiation, then creating practical ways to prevent avoidable patient drop-off. Solutions can include affordability support, patient access services, improved pharmacy workflows, clearer communications, and better measurement.
How can marketers reduce post-prescription friction?
Marketers can work with market access, patient services, analytics, and commercial teams to identify common failure points. They can also make support options easier to find and ensure patients understand what to do when coverage problems occur.
Does reducing abandonment mean every rejected claim should become a cash transaction?
No. The appropriate solution depends on the product, patient, coverage situation, program eligibility, and applicable requirements. The broader lesson is to create clear pathways so patients are not left without understandable next steps.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
